A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies
- PMID: 12834180
- DOI: 10.5414/cnp59463
A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies
Abstract
Calcific uremic arteriolopathy (calciphylaxis) is one of the more devastating complications that can develop in patients with chronic renal failure. This disorder is associated with calcium-phosphorus deposition in the subcutaneous arterial vessels and presents as a progressive ischemic necrosis of the skin resulting in large subcutaneous ulcerations with eschar formation. Mortality rates are substantially greater in chronic renal failure patients with calciphylaxis, and the major cause of death is infection and sepsis. We have developed a treatment strategy that employs a combination of therapies, which is based on reducing the known risk factors for the development of calciphylaxis as well as utilization of a number of treatment modalities that have been proven successful in the treatment of this disorder.
Similar articles
-
Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.Clin Nephrol. 2002 Sep;58(3):238-43. doi: 10.5414/cnp58238. Clin Nephrol. 2002. PMID: 12356195
-
Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy.Clin Nephrol. 2008 Sep;70(3):261-4. doi: 10.5414/cnp70261. Clin Nephrol. 2008. PMID: 18793571
-
Cutaneous necrosis from calcific uremic arteriolopathy.Am J Kidney Dis. 1998 Sep;32(3):384-91. doi: 10.1053/ajkd.1998.v32.pm9740153. Am J Kidney Dis. 1998. PMID: 9740153 Review.
-
The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.Ther Apher Dial. 2005 Feb;9(1):16-23. doi: 10.1111/j.1774-9987.2005.00216.x. Ther Apher Dial. 2005. PMID: 15828901
-
Calcific uremic arteriolopathy (calciphylaxis) calls into question the validity of guidelines of diagnosis and treatment.J Dermatolog Treat. 2020 Aug;31(5):545-548. doi: 10.1080/09546634.2019.1618435. Epub 2019 May 31. J Dermatolog Treat. 2020. PMID: 31075991 Review.
Cited by
-
Medial vascular calcification revisited: review and perspectives.Eur Heart J. 2014 Jun 14;35(23):1515-25. doi: 10.1093/eurheartj/ehu163. Epub 2014 Apr 16. Eur Heart J. 2014. PMID: 24740885 Free PMC article. Review.
-
Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain.Curr Pain Headache Rep. 2021 Jun 4;25(8):50. doi: 10.1007/s11916-021-00965-0. Curr Pain Headache Rep. 2021. PMID: 34086132 Review.
-
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17. Clin J Am Soc Nephrol. 2015. PMID: 25887067 Free PMC article. Clinical Trial.
-
Calcific Uremic Arteriolopathy: A Case Series and Review from an Inner-City Tertiary University Center in End-Stage Renal Disease Patients on Renal Replacement Therapy.Int J Nephrol. 2021 Feb 12;2021:6661042. doi: 10.1155/2021/6661042. eCollection 2021. Int J Nephrol. 2021. PMID: 33628505 Free PMC article.
-
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.Core Evid. 2005;1(1):43-63. Epub 2005 Mar 31. Core Evid. 2005. PMID: 22496676 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources